Physician profile
Adan Rios
NPI 1942378799
$16,503.06
in general payments reported to CMS, 2019-2025
20 companies · $11K in 2025
The $11K reported for 2025 was more than what 89% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $251 · 2020: $121 · 2022: $302 · 2023: $328 · 2024: $4,996 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Travel and Lodging: $3,214 · Food and Beverage: $1,915.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,701.25 |
| Travel and Lodging | $3,214.15 |
| Food and Beverage | $1,914.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $8,598.77 | 2024-2025 | Yescarta |
| Genmab U.S., INC. | $2,385.06 | 2024-2025 | Epkinly |
| Adaptive Biotechnologies Corporation | $2,202.66 | 2022-2024 | Clonoseq |
| Janssen Biotech, INC. | $1,937.33 | 2023-2025 | Darzalex, Tecvayli |
| Astellas Pharma US INC | $292.46 | 2019-2020 | |
| Tempus Ai, INC | $244.49 | 2024 | Xt Cdx |
| Pierre Fabre Pharmaceuticals, INC. | $226.27 | 2024 | Hemangeol |
| Amgen INC. | $160.82 | 2023-2024 | Kyprolis |
| Allotrope Medical, INC | $159.53 | 2022 | |
| Jazz Pharmaceuticals INC. | $148.62 | 2023 | Vyxeos |
| Novartis Pharmaceuticals Corporation | $66.21 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $32.30 | 2025 | Calquence |
| Genzyme Corporation | $19.05 | 2025 | |
| Tactile Systems Technology INC | $16.68 | 2024 | Flexitouch Plus, Entre Plus |
| Shionogi INC | $12.81 | 2019 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adan Rios listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.